A Study Of Relation Between Thrombin Activatable Fi Brinolysis Inhibition And Coronary Heart Disease.

Objective:To investigate the association between gene polymorphism and plasma level of thrombin activatable fibrinolysis inhibition(TAFI) and Coronary Heart Disease.Methods:This study was conducted with 102 health adults as control and 101 CHD patients to determine genotype.Genotype was determined by polymerase chain reaction -restriction fragment length polymorphism (PCR-RFLP)for the G505A polymorphism in TAFI gene coding sequence.And there are case-control design in 54 patients among the total with Coronary Heart Disease(CHD)approved by coronary angiography and 25 control subjects who are free from coronary artery disease to examine the plasma TAFI:Ag concentration.Baseline plasma TAFI:Ag concentration was measured by enzyme-linked immunosorbent assay(ELISA).Results:The normal mean of plasma TAFI:Ag is(79.7±8.845) %,reference value range is 65.2%-94.2%.The mean of plasma TAFI:Ag for CHD patients is(72.448±15.016)%,furthermore this variance are significant different as compared with the controls(P＜0.05).The level of plasma TAFI:Ag in acute myocardial infarction(AMI)group is little higher than that of the unstable angina pectoris(UAP)group,there is no significant.There is not significant difference between tne Gensini score＜20,20-40and Gensini score＞40.The level of plasma TAFI:Ag were not statistically different among CHD patients with one,two,three or more significantly diseased vessels(P＞0.05).TAFI levels did not correlate with extent of coronary atherosclerosis.The result of individual polymorphisms analysis showed that the genotyping frequencies of G505A were A505A 17(8.3%),G505A86(42.4%)and G505G100(49.3%), respectively.Chi-square analyses showed that the difference of these genotyping frequencies between the cases and controls was not significant (P＞0.05).The frequency of AA genotype of G505A polymorphism were not statistically different among CHD patients with one,two,three or more significantly diseased vessels(P＞0.05).Conclusions:The level of plasma TAFI:Ag in Chinese is lower than that of European.there is a lower level of plasma TAFI:Ag in ACS patients as compared with the controls.The result indicate that TAFI play a role in the procession of CHD,and considered as a chemical marker in the development of ACS.The level of plasma TAFI:Ag may be not a potential role in predict the severity of CHD.The G505A polymorphism may not be useful as a predictor of CHD and the severity of coronary atherosclerosis.